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Abstract. Onbrez Breezhaler® is a low-resistance capsule-based device that was
developed to deliver indacaterol maleate. The study was designed to investigate the effects
of both maximum ﬂow rate (MIF) and inhalation volume (Vin) on the dose emission of
indacaterol 150 and 300 μg dose strengths after one and two inhalations using dose unit
sampling apparatus (DUSA) as well as to study the aerodynamic characteristics of
indacaterol Breezhaler® using the Andersen cascade impactor (ACI) at a different set of
MIF and Vin. Indacaterol 150 and 300 μg contain equal amounts of lactose per carrier.
However, 150 μg has the smallest carrier size. The particle size distribution (PSD) of
indacaterol DPI formulations 150 and 300 μg showed that the density of ﬁne particles
increased with the increase of the primary pressure. For both strengths (150 μg and 300 μg),
ED1 increased and ED2 decreased when the inhalation ﬂow rate and inhaled volume
increased. The reduction in ED1 and subsequent increase in ED2 was such that when the Vin
is greater than 1 L, then 60 L/min could be regarded as the minimum MIF. The Breezhaler
was effective in producing respirable particles with an MMAD ≤5 μm irrespective of the
inhalation ﬂow rate, but the mass fraction of particles with an aerodynamic diameter <3 μm is
more pronounced between 60 and 90 L/min. The dose emission of indacaterol was
comparable for both dose strengths 150 and 300 μg. These in vitro results suggest that a
minimum MIF of 60 L/min is required during routine use of Onbrez Breezhaler®, and
conﬁrm the good practice to make two separate inhalations from the same dose.
KEY WORDS: aerodynamic dose emission characteristics; indacaterol; Onbrez Breezhaler®; inhalation
volume; maximum inhalation ﬂow.
INTRODUCTION
Inhaled therapy is the mainstay treatment of choice
to control the symptoms of asthma and chronic obstruc-
tive pulmonary disease (COPD) (1) using either metered
dose inhalers (MDIs) or dry powder inhalers (DPIs). The
quality and the amount of the emitted dose from a DPI
depend on the patient’s inhalation manoeuvre, the type of
device and its formulation (2,3). Each inhalation manoeu-
vre is characterised by a ﬂow versus time proﬁle which
includes the inhaled volume. During use, inhalation ﬂow
interacts with the resistance inside the DPI to generate a
‘force’ that deaggregates the formulation such that active
drug particles, with the greatest likelihood of lung
deposition, are entrained in the air stream as it leaves
the device. The inhaled volume ensures that the dose is
emptied from the metering cup/capsule (the latter applies
if the DPI is a single-dose capsule product). When
inhaling from a single-dose capsule DPI product, it is
essential that the inhaled volume is sufﬁcient to empty the
entire dose out of the capsule. It is for this reason that
the patient information leaﬂet (PIL) for these DPIs should
direct patients to make two separate inhalation manoeu-
vres from each prepared capsule dose (1,4).
The resistance of a DPI is an intrinsic value which
depends on the design of the inhalation channel, the metering
cup and the air inlets (5). DPIs can be classiﬁed into four
resistance groups (low, medium, medium-high, high) with
respect to the inhalation ﬂow required to produce a pressure
drop of 4 kPa (1,6). Patient inhalation ﬂows through high-
resistance devices are naturally lower than those having a
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lower resistance (7–10). However, the internal ‘force’ created
by a low ﬂow through a DPI with high resistance is higher
than that created by a faster ﬂow through a DPI with low
resistance (11). The Breezhaler® is a low-resistance device
and has a resistance of 0.0177 (kPa)0.5 (min L−1) (6).
Patients with COPD have reduced inspiratory capacities
together with low inhaled volumes (12), and so many use sub-
optimal inhalations when using DPIs which means that the
dose they inhale is reduced.
Inhalers play an important role in the management of
patients with COPD, and it is being recognised that the
choice of the inhalation device appears to be as important as
that of the drug molecule (8,13). Inhaled long-acting bron-
chodilators are used for the treatment of patients with
moderate and more severe COPD (14), and now, agents are
available for once-daily administration. Indacaterol is an
inhaled, once-daily, ultra-long-acting β2-agonist (15). The
indacaterol is mixed with lactose (to increase the bulk and
enhance powder ﬂow of the formulation). It is packaged in
transparent hard gelatine capsules each containing either 75,
150 or 300 μg of indacaterol inhalation powder inhaled from a
Breezhaler® inhaler. Published data shows that patients with
stable COPD were able to generate, on average, a maximum
inhalation ﬂow (MIF) of 72 L/min with a range of 47–99 to
94.8 L/min (range, 52–133 L/min) and mean inhaled volumes
(Vin) of 1.7 L, range of 1 to 2.2 L (8,16,17). In vitro dose
emission studies focus on identifying the optimal inhalation
ﬂow rate for dose deaggregation; however, this optimal ﬂow
may not be achievable in real-life use by the patient. The
multivariate statistical approach study carried out by Buttini
et al. demonstrates that the ﬁne particle mass emitted from
the single-dose inhaler device has signiﬁcantly decreased
when the minimum inspiratory volume was used to operate
the device (18). The information that is most clinically
relevant is to identify the type of dose emitted when low
inhalation ﬂows and inhaled volumes are used. This is very
important for patients with COPD because these patients can
only use low inhalation ﬂows and low inhaled volumes
(11,12). Therefore, the primary aim of this work was to
investigate a range of inhalation ﬂow rates (28.3, 60, 90 and
120 L/min) and volumes (500, 750, 1000, 1500 and 2000 mL)
on the dose emission from 150 and 300 μg indacaterol Onbrez
Breezhaler® (Novartis Pharmaceuticals Ltd., UK) using two
separate inhalations. Secondly, this study was conducted to
determine the aerodynamic characteristics of indacaterol
emitted dose using the Andersen cascade impactor (ACI) at
a MIF of 28.3, 60 and 90 L/min and 1, 1.5, 2 and 4 L inhaled
volumes.
MATERIAL AND METHODS
Characterisation of the Indacaterol Onbrez Breezhaler® 150
and 300 μg Powder Formulations by Scanning Electron
Microscope
Scanning electron microscopy (SEM) investigations of
the shape, particle size and surface texture of indacaterol
and the lactose in the Onbrez Breezhaler® 150 and 300 μg
(Novartis Pharmaceuticals, CH) products were carried out
using a Jeol 6060LV SEM (Jeol Ltd., UK). A sample of
the powder formulation was scattered onto the aluminium
stage stub, by a gentle tapping motion to provide a thin
layer that was suitable to view the particles. The
movement of the sample was restricted by adhering the
sample to a double-sided conductive carbon adhesive tape
(Agar Scientiﬁc, UK). As the sample is non-conductive, it
was required to coat the sample with a thin layer of gold
(15–20 nm) (Quorum Technologies Ltd., UK) using a
Quorum SC7620 sputter coater (Quorum Technologies
Ltd., UK).
Particle Size Measurement Using Dry Dispersion Laser
Diffraction
Particle size measurements were carried out using a
Sympatec HELLO/RODOS (Sympatec GmbH, Clausthal-
Zellerfel, Germany). The methodology used was similar to
the one reported by Jaffari et al. except that the primary
range employed was in the range of 0.12–4.51 bar to
investigate the indacaterol Breezhaler particle distribution
density when the primary pressure changed (19).
Chemicals and Solvents
Indacaterol maleate (analytical grade) was purchased
from Medchem (USA). Potassium dihydrogen orthophos-
phate, orthophosphoric acid and methanol high-performance
liquid chromatography (HPLC) grade were obtained from
Fisher Scientiﬁc (UK). The water was ultra-puriﬁed for
HPLC use. Indacaterol Onbrez Breezhaler®, a nominally
labelled dose of 150 μg (batch number B0018; expiry date 04/
2016) and 300 μg (batch number B0011; expiry date 08/2016)
indacaterol maleate per dose in a size 3 transparent hard
gelatine capsule (Novartis Pharmaceuticals, CH), was ob-
tained from a local supplier and so were those available for
patient use. The amount of lactose in both formulations is
almost the same—24.8 and 24.6 mg for both 150 and 300 μg
dose strengths, respectively.
Dose Emission, Residual Amount and Recovered Dose
from 150 and 300 μg Onbrez Breezhaler® DPIs
The total emitted dose (TED) was determined using a
DPI dose unit sampling apparatus (DUSA, Copley Scientiﬁc,
UK) after two separate inhalations. The dose of 150 or 300 μg
indacaterol maleate emitted from an Onbrez Breezhaler® was
determined using the DPI dose emission method described in
the pharmacopoeia (20) except that a range of ﬂows and
volumes have been used instead of the ﬂow that produces a 4-
kPa pressure drop and inhaled volume of 4 L. For each
determination, two DUSAs (Copley Scientiﬁc Ltd., UK) were
used so that the dose emitted from the ﬁrst inhalation (ED1)
and a second inhalation (ED2) could be measured separately.
ED1 and ED2 were summed to provide the TED. The
emitted dose from the Onbrez Breezhaler® inhalers was
measured by collecting one individual dose at different MIFs
and Vins. For each determination, one capsule was inserted
into the device according to the manufacturer’s instructions in
the PIL. For each inhalation ﬂow, the emitted dose of three
separate, single unit capsule doses was determined (n = 3).
Following each dose emission into the DUSA, the emitted
dose was recovered using an acetonitrile:water (60:40 v/v)
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solution. The ﬁlter was immersed into an appropriate volume
of this washing solution and then sonicated for 15 min to
detach and dissolve the indacaterol entrained on the ﬁlter.
After the second inhalation, the device and capsules were
washed separately to determine any residual amount left in
the capsules (RACAP) and device (RADEV). The total
residual amount (TRA) was calculated by summing
RACAP + RADEV. The total recovered dose (TRD) was
calculated as the sum of the TED + TRA.
Determination of the Aerodynamic Characteristics
of the Emitted Dose and Collection of the Residual
Amount of Indacaterol
The aerodynamic characteristics of indacaterol 150 and
300 μg from an Onbrez Breezhaler® were determined at MIF
values of 28.3, 60 and 90 L/min with Vin values of 1, 1.5, 2 and
4 L using the Andersen Cascade Impactor (ACI) and the
USP throat. At 28.3 L/min, standard ACI stages from 0 to 7
were used, whilst to enable ACI to operate at 60 L/min,
stages 0 and 7 were replaced with stages −1 and −0. To enable
determinations at 90 L/min, stages −2A, −1A and −0 were
used instead of stages 0, 6 and 7. The stages’ cut-off diameters
at 28.3 L/min MIF in descending order were 9.0, 5.8, 4.7, 3.3,
2.1, 1.1, 0.7 and 0.4 μm, respectively. At 60 L/min, the stages’
cut-off diameters were 8.6, 6.5, 4.4, 3.2, 1.9, 1.2, 0.55 and
0.26 μm. At 90 L/min, the stages’ cut-off diameters were 8.0,
6.5, 5.2, 3.5, 2.6, 1.7, 1.0 and 0.22 μm. For each calibrated ﬂow
rate (28.3, 60 and 90 L/min), a designed pre-separator was
connected to the ACI. The collection plates were sprayed
with silicone lubricant (Pro-Power Premier Farnell plc, UK)
and allowed to dry at room temperature before use. The ACI
was connected to a vacuum pump (HCP, Copley Scientiﬁc
Ltd., UK) via the critical ﬂow controller (model TPK Copley
Scientiﬁc Ltd., UK). The ACI stages were assembled with
10 mL of 60% methanol:40% ultra-puriﬁed water (% v/v) in
the pre-separator, and a glass ﬁbre GF50 (Whatman, UK)
ﬁlter was placed in the ﬁnal stage. For each determination,
three capsules from 150 μg were used, and for indacaterol
300 μg, only two capsules were used. Each dose was prepared
according to the manufacturer’s recommended patient in-
structions (in the PIL). Three separate determinations were
made for each dose strength using MIF values of 28.3, 60 and
90 L/min at Vins of 1, 1.5, 2 and 4 L. The residual amount was
determined by washing the capsules and device separately
using 10 mL of the washing solution.
HPLC Quantification of Indacaterol
After each determination, the mouth piece adaptor
(MP), induction port (IP), ACI collecting plates, capsules
and device were separately rinsed with various volumes of the
acetonitrile 60%:water 40% washing solution: MP (5 mL), IP
(10 mL), pre-separator (20 mL), collecting plates, the ACI
ﬁlter, capsules and device (10 mL each) of the washing
solution containing 60% methanol:40% ultra-puriﬁed water
(v/v). The amount of indacaterol from these washings was
determined using a validated HPLC method. The chromato-
graphic separation was performed at 40°C using a C18
Kinetex (250 mm × 4.6 mm, 5 μm) column (Phenomenex®,
USA). The mobile phase was methanol:buffer (25 mM
potassium dihydrogen orthophosphate 60:40% v/v). Before
use, the mobile phase was ﬁltered through a membrane ﬁlter
(47 mm diameter, pore size 0.45 μm). The mobile phase was
delivered at a ﬂow rate of 1 mL/min; the injection volume was
20 μL, UV detection at 259 nm (D200, Shimadzu, Japan) and
a run time of 7 min. The detector response was shown to be
linear over the range of 0.1–10 μg/mL. Each solution was
injected in triplicate. The response for indacaterol concentra-
tions gave a correlation coefﬁcient that identiﬁed linearity
(r(2) = 0.99; y = 2.0515x − 0.0006; n = 9). The limit of
detection (LOD) and limit of quantiﬁcation (LOQ) for
indacaterol were 0.05 and 0.17 μg/mL, respectively.
Measurement of Dose Uniformity
The indacaterol content and uniformity in the 150- and
300-μg Onbrez Breezhaler® products were identiﬁed by
analysing the quantity of indacaterol maleate in the capsule.
The contents of each capsule were emptied into a 100-mL
volumetric ﬂask, and then the empty capsule was added
before the washing solution. Six capsules were taken ran-
domly from each pack of indacaterol 150 and 300 μg, and
each solution was assayed in duplicate using the HPLC
method described above. The coefﬁcient of variation (%
CV) was used to assess the homogeneity of indacaterol 150
and 300 μg powder formulations.
Data Analysis
The Copley Inhaler Testing Data Analysis Software
(CITDAS version 2.0, Copley Scientiﬁc Ltd., UK) was used
to calculate the aerodynamic dose emission parameters.
When using the ACI, the TED was obtained from the
cumulative amounts of indacaterol deposited in the
induction port (USP throat), the pre-separator and all
the stages of the ACI. The ﬁne particle dose (FPD) of
indacaterol was the mass associated with particles <5 μm.
The ﬁne particle dose was expressed as the percentage of
the label claim, and the ﬁne particle fraction (FPF) was
the FPD divided by the TED. The mass median aerody-
namic diameter (MMAD) was the size corresponding to
the 50th percentile of the cumulative mass-weighed
distribution of the amount deposited in the ACI. The
TRD was calculated as the sum of the TED and the RA.
A one-way analysis of variance (ANOVA) was used
to compare ED1, ED2, TED, RA, FPD, %FPF and
MMAD over the range of inhalation ﬂow rates and
volumes.
A two-way ANOVA was used to compare the emitted
dose after one and two inhalations; in addition, Tukey’s test
was used to determine the difference in the ED, RA, TED,
TRD, FPD, %FPF and MMAD at different inhalation ﬂows
and volumes.
RESULTS AND DISCUSSION
The Onbrez Breezhaler® formulation, like many DPI
devices, contains a blend of the micronised drug with α-
lactose monohydrate carrier. Each capsule contains
indacaterol maleate equivalent to 150 or 300 μg indacaterol.
Onbrez Breezhaler® 150 and 300 μg are formulated with
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similar amounts of carrier, i.e. 24.8 mg for the 150-μg
indacaterol and 24.6 mg for the 300-μg dose (21), corre-
sponding to a 0.6% w/w and 1.2% w/w drug/lactose ratio for
150 and 300 μg indacaterol, respectively. SEM micrographs of
the indacaterol formulations are shown in Supplement 1. This
ﬁgure shows that the carrier particles for 150 μg are much
smaller than the 300-μg indacaterol formulation, with the
majority of carrier particles smaller than 50 μm. The SEM
close view reveals the presence of tomahawk-shaped carrier
with associated ﬁne particles ≤5 μm (Supplement 1c and d).
The lactose carrier forms the major proportion of the DPI
formulation, and any change in the physio-chemical proper-
ties of the carrier particles such as the size, shape, surface
texture, grade and polymorphic form has the potential to alter
drug deposition proﬁle (22,23). The particle size distribution
(PSD) of indacaterol DPI formulations 150 and 300 μg at
different primary pressures measured using a Sympatec
HELLOS/RODOS dry dispersion laser diffraction is shown
in the ﬁgures (Supplements 2 and 3), respectively. The ﬁgures
showed a broad PSD for both indacaterol formulations
containing particles in the size range from approximately 1.5
to 70 μm. The primary pressure used was not sufﬁcient to
affect the shape of the size distribution. Nevertheless, it
affected the particles’ distribution density. The density of ﬁne
particles increased with the primary pressure increase which
could occur as result of the breakage of agglomerates
(Supplements 2 and 3). Despite the differences observed in
the carrier particle size, size distribution and drug to carrier
ratio, yet both formulations produced a good drug content
uniformity (% CV < 1.8%) and a percentage recovery of
100% (Table I).
Tables II and III summarise the dose emission results
after the ﬁrst (ED1) and after the second inhalation
(ED2) as well as the TED for the 150- and 300-μg
indacaterol products as a function of MIF and Vin. The
ED1 signiﬁcantly increased (p < 0.05), whereas the ED2
decreased with increasing of the MIF and Vin. At the low
inhalation ﬂow rate (28.3 L/min), the ﬁrst inhalation was
not sufﬁcient to withdraw most of the dose from the
capsule and the second inhalation was necessary to empty
the capsule (Fig. 1). The results conﬁrm the recommen-
dation to make two separate inhalations (1) especially
when the low ﬂow rate is used. The Vin contributed to
the capsule emptying after the ﬁrst inhalation. At the
higher inhalation ﬂow rate (120 L/min), most of the dose
was emitted from the capsule after the ﬁrst inhalation,
and only small amounts of the drug were left in the
capsule after the second inhalation (Tables II and III).
The impact of the inhaled volume with regard to dose
emptying was more pronounced at the low ﬂow rate
Table I. Mean, Percent Recovery and % Coefﬁcient of Variation (%
CV) in Indacaterol Maleate Content Contained in a Single Unit 150
and 300 μg Indacaterol Onbrez Breezhaler® (n = 6)
Indacaterol maleate
dose strength
Mean dose per
capsule ± SD
% CV
150 μg 151.32 ± 2.68 1.77
300 μg 301.46 ± 4.74 1.57
Table II. Mean (SD) of Dose Emission Data of 150 μg Indacaterol Dose after Two Separate Inhalations
Vin (mL) ED1 (μg) ED2 (μg) TED (μg) TRA (μg) TRD (μg)
Inhalation ﬂow rate 28.3 L/min
500 96.26 (1.89) 22.68 (1.74) 118.94 (2.72) 31.63 (2.51) 150.57 (0.37)
750 104.90 (2.01) 18.40 (1.65) 123.30 (0.76) 28.41 (1.52) 151.71 (1.86)
1000 114.98 (2.71) 9.72 (0.66) 124.70 (3.27) 20.05 (0.23) 144.75 (3.24)
1500 121.23 (3.08) 6.58 (1.92) 127.81 (1.16) 17.78 (0.38) 145.59 (1.12)
2000 123.13 (3.07) 4.44 (0.56) 127.57 (2.68) 17.88 (0.80) 145.45 (5.03)
Inhalation ﬂow rate 60 L/min
500 120.14 (5.26) 10.50 (1.27) 130.64 (6.46) 19.43 (0.65) 150.07 (7.04)
750 123.90 (2.41) 7.72 (2.86) 131.62 (1.57) 18.15 (0.88) 149.77 (2.27)
1000 129.16 (3.36) 4.75 (0.66) 133.91 (3.11) 15.97 (0.61) 149.88 (3.11)
1500 131.73 (4.10) 3.72 (0.91) 135.45 (4.65) 13.79 (0.70) 149.24 (5.28)
2000 134.27 (4.32) 2.50 (0.70) 136.77 (3.96) 13.37 (0.75) 150.14 (4.25)
Inhalation ﬂow rate 90 L/min
500 125.83 (4.58) 8.76 (2.02) 134.59 (3.84) 14.76 (1.54) 149.35 (2.97)
750 128.16 (3.62) 7.19 (1.61) 135.35 (5.23) 13.37 (0.14) 148.72 (5.10)
1000 133.87 (1.63) 3.07 (1.19) 136.94 (2.38) 13.33 (0.09) 150.27 (2.45)
1500 136.08 (4.45) 2.13 (0.63) 138.21 (3.92) 12.50 (0.24) 150.71 (5.52)
2000 137.15 (4.93) 1.92 (0.95) 139.07 (5.76) 12.22 (0.73) 151.29 (3.48)
Inhalation ﬂow rate 120 L/min
500 130.18 (4.37) 6.24 (1.59) 136.42 (5.32) 12.42 (0.92) 148.84 (6.18)
750 136.03 (4.77) 3.41 (0.94) 139.45 (5.40) 11.33 (1.80) 150.77 (7.12)
1000 138.07 (7.98) 3.41 (1.64) 141.48 (3.39) 11.71 (1.63) 153.19 (8.00)
1500 140.42 (6.98) 2.76 (0.47) 143.17 (6.55) 9.94 (0.54) 153.12 (6.62)
2000 142.43 (1.94) 1.28 (0.73) 143.71 (1.74) 8.65 (0.89) 152.36 (2.53)
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(Tables II and III). It is widely accepted that breath-
activated DPIs are often associated with ﬂow rate-
dependent changes in the emitted dose (24–27). Increasing
the MIF from 28.3 to 120 L/min resulted in a signiﬁcant
(p < 0.05) increase in the total emitted dose.
Overall dose emission was reduced below a MIF of 60 L/
min and Vin of 1 L. Since the reported MIF and Vin of some
COPD patients were found to be below these values
(8,16,17), then not all patients will inhale the prescribed dose
when using the Onbrez Breezhaler®.
The resistance of a DPI can be classiﬁed with respect to
the inhalation ﬂow required to produce a pressure drop of
4 kPa. This value was chosen because it is the one
recommended by pharmacopoeia (20) for the in vitro charac-
terisation of the dose emitted from a DPI. A device that is
characterised as having a low resistance requires an inspira-
tory ﬂow of 90 L/min to produce this pressure drop (1). We
found that the ﬂow rate required to achieve a 4-kPa pressure
drop through the Breezhaler® was around 100 L/min which is
in line with (17,28). This conﬁrms that the Breezhaler® is a
low-resistance device.
In the case of the indacaterol Breezhaler®, irrespective
of the sampling apparatus used (DUSA or ACI), the TED is
almost doubled with increasing indacaterol dose from 150 to
300 μg, suggesting a linear relationship between the inhaled
dose and the delivered dose in vitro. The TEDACI is
equivalent to ED1 recovered from DUSA1. At the same
MIF (90 L/min) and Vin (2 L), the TEDACI was generally
smaller than ED1. The ACI is composed of many stages,
and there will always be some drug losses during the
washing procedure of the ACI, whereas the DUSA is
relatively easy to wash and obtains up to 100% drug
recovery. The washing procedure of either DUSA or ACI
was carefully conducted as shown from the TRD which was
around 100% for DUSA (Tables II and III) and >92% for
ACI (Tables IV and V).
Capsule-based DPIs can be limited by powder reten-
tion in the capsule and device, which leads to a reduction in
the emitted dose (29). The drug retention could be
minimised by coating the drug capsule and delivery device
with pharmaceutically acceptable force-control agents (30).
Irrespective of the dose strength, the residual amount in the
capsule after two separate inhalations (RA/Cap), residual
amount in the device (RA/Dev) and the total residual
amount in capsule and device (TRA/RA(Cap) + RA(Dev))
were decreased with increasing of MIF and Vin (Tables II
and III). The RA(Cap) after two separate inhalations is
much smaller than the RA(Dev). Thus, inhaling twice from
the capsule, inhaling forcefully and prolonging the inhala-
tion time contribute all to the reduction in the TRA. The
RA is about twofold for 300 μg indacaterol (Table III) in
comparison to 150 μg using DUSA (Table II) or ACI
(Tables IV and V).
The inhaled volumes used to quantify the aerodynamic
particle size distribution of inhaled indacaterol exceed the
internal volume of the ACI (1155 mL) (31) to allow
sufﬁcient sampling time for the aerosol bolus transfer from
the inhaler device to distal stages of the ACI. The ACI data
illustrate the impact of the Vin and MIF increase on the
aerodynamic characteristics of indacaterol emitted dose.
The results of the FPD as a function of the Vin at different
MIFs for both dose strengths 150 and 300 μg are shown in
Fig. 2a, b, respectively. The FPD signiﬁcantly (p < 0.05)
increased with both the Vin and the MIF irrespective of the
Table III. Mean (SD) of Dose Emission Data of 300 μg Indacaterol Dose after Two Separate Inhalations
Vin (mL) ED1 (μg) ED2 (μg) TED (μg) TRA (μg) TRD (μg)
Inhalation ﬂow rate 28.3 L/min
500 199.15 (12.86) 35.07 (5.51) 234.21 (9.46) 57.20 (1.40) 291.41 (13.84)
750 214.89 (12.81) 32.25 (1.84) 247.14 (14.20) 47.71 (1.45) 294.85 (10.03)
1000 242.03 (11.55) 11.49 (5.13) 253.52 (11.00) 36.16 (0.84) 289.68 (11.42)
1500 244.82 (12.01) 9.68 (3.34) 254.51 (10.47) 35.50 (1.60) 290.01 (14.74)
2000 249.43 (11.15) 5.74 (1.77) 255.17 (11.98) 31.47 (1.13) 286.63 (13.10)
Inhalation ﬂow rate 60 L/min
500 228.89 (9.28) 19.66 (8.79) 248.55 (13.59) 42.94 (1.40) 291.49 (12.91)
750 242.91 (5.23) 9.34 (2.13) 252.25 (6.91) 38.74 (1.33) 290.99 (8.22)
1000 253.20 (11.25) 5.17 (1.05) 258.37 (10.25) 35.42 (0.44) 293.79 (10.32)
1500 255.77 (7.15) 4.03 (2.07) 259.80 (15.83) 32.70 (0.78) 292.50 (11.07)
2000 259.17 (9.53) 3.40 (0.56) 262.57 (9.61) 30.47 (2.07) 293.04 (11.89)
Inhalation ﬂow rate 90 L/min
500 253.98 (3.46) 11.78 (2.44) 265.76 (1.91) 33.07 (1.17) 298.83 (7.84)
750 264.76 (7.36) 8.75 (5.51) 273.51 (8.65) 26.65 (1.14) 300.16 (9.60)
1000 270.32 (6.58) 5.04 (1.79) 275.36 (4.79) 24.63 (1.69) 299.99 (6.48)
1500 274.72 (7.18) 2.81 (0.72) 277.53 (6.73) 22.94 (1.20) 300.47 (7.00)
2000 276.45 (8.63) 2.83 (1.56) 279.28 (7.19) 23.77 (1.15) 303.05 (6.24)
Inhalation ﬂow rate 120 L/min
500 261.25 (11.38) 8.84 (0.16) 270.10 (19.22) 22.46 (1.72) 292.55 (1.87)
750 268.31 (4.21) 5.61 (0.64) 273.92 (4.77) 19.82 (1.71) 293.75 (6.44)
1000 270.58 (3.57) 5.02 (0.37) 275.59 (3.19) 19.02 (0.80) 294.62 (2.99)
1500 278.02 (12.89) 3.18 (0.98) 281.20 (13.51) 15.60 (1.90) 296.80 (10.69)
2000 280.87 (12.04) 2.91 (0.99) 283.79 (13.03) 12.80 (1.17) 296.58 (13.20)
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dose strength. The FPD was almost doubled when the dose
strength increased from 150 to 300 μg (Fig. 2a, b) across all
MIFs and Vins; however, as a percentage of the nominal
dose, the FPD would be almost similar for both dose
strengths suggesting the reliability of the Breezhaler in
delivering a consistent drug dosing in vitro. Prolonging the
Vin is more critical especially when low MIF is used. For
example, using an inhaled volume of 4 L at 28.3 L/min
would provide similar FPD to 90 L/min and 1 L inhaled
volume (Fig. 2). Thus, prolonging the inhalation volume is
essential when high MIF cannot be achieved. The increase
in FPD is more pronounced between 28.3 and 60 L/min, and
the rate of increase in the FPD between 60 and 90 L/min is
generally reduced. Thus, 60 L/min could be considered as a
threshold MIF to operate the Breezhaler, which can be
achieved easily achieved in practice due to the low
resistance of this device. For example, using the same
patients, a mean peak inspiratory ﬂow (PIF) of 72 L/min
was generated with the Breezhaler® device compared with a
mean PIF of only 36 L/min with the HandiHaler® (32). The
results of the EFPD (<3 μm) for both dose strengths (150
and 300 μg) are shown in Fig. 3. A similar trend was
observed for EFPD (<3 μm) for both dose strengths with
increasing the MIFs and Vins. The high proportion of
EFPDs would improve the deposition in the peripheral
airways in the lungs, and this is considered beneﬁcial for the
management of COPD (33,34). Our study showed that both
the MIFs and Vins are important in maximising the EFPD
of indacaterol (Fig. 3). GSD values are >1.2 μm (Tables IV
and V) suggesting polydispersity of the aerosol; this
Fig. 1. The dose emission of indacaterol after one (ED1) and two (ED2) inhalations as percentage of the nominal dose. a The results of dose
emission after two inhalations using indacaterol 300 μg dose strength. b The results of dose emission using indacaterol 150 μg dose strength
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polydispersity is more likely to inﬂuence drug distribution in
the airways. This polydispersity contains substantial mass
fractions of particles smaller than 5 μm (Fig. 4a, b). The
greatest decrease in MMAD was observed between 28.3
and 60 L/min across all Vins used, and the increase of the
MIF above 60 L/min did not bring much difference in the
MMAD, suggesting that 60 L/min is the minimum MIF to
operate the Breezhaler. An MMAD <5 μm is considered to
be necessary for sufﬁcient airway deposition (35). The
differences in FPF <5 μm between different ﬂow rates and
volumes are also strongly reﬂected in the differences in the
EFPF (<3 μm). The turbulence generated at high ﬂow rates
60 and 90 L/min was able to generate sufﬁcient shear forces
between drug-drug particles. Such phenomenon would be
able to enhance particle dispersion leading to the formation
of smaller particle size (36) as shown in Fig. 3. Prolonging
inhaled volume may have also provided particles with
sufﬁcient time of ﬂight allowing drug-drug particle detach-
ment. The performance of the Breezhaler is dependent on
both inhalation ﬂow rate and volume. The increase in FPD
is more pronounced between 28.3 and 60 L/min. Prolonging
the Vin is more critical especially when low MIF is used.
The Breezhaler was effective in producing respirable
particles with an MMAD <5 μm irrespective of the
Table IV. Mean (SD) of the Aerodynamic Characteristics of the Indacaterol 150-μg Dose Emission at Different MIFs and Vins [n = 3]
Vin (mL) FPD (μg) TED (μg) % FPF EFPD (μg) RA (μg) % TRD MMAD (μm) GSD
MIF = 28.3 L/min
1000 36.4 (0.4) 105.7 (1.5) 34.5 (0.2) 20.1 (0.1) 29.3 (1.3) 90.0 (1.4) 3.5 (0.1) 1.8 (0.1)
1500 40.5 (0.2) 111.6 (0.9) 36.3 (0.4) 21.5 (0.4) 22.3 (0.8) 89.3 (0.9) 3.4 (0.0) 1.9 (0.0)
2000 42.9 (0.1) 115.4 (1.3) 37.2 (0.3) 25.2 (0.1) 21.7 (1.3) 91.4 (1.1) 3.3 (0.1) 1.8 (0.1)
4000 46.8 (0.5) 120.0 (0.8) 39.1 (0.1) 27.6 (0.0) 18.9 (0.4) 92.6 (0.7) 3.2 (0.1) 1.8 (0.1)
MIF = 60 L/min
1000 43.2 (0.5) 119.4 (1.1) 36.2 (0.7) 28.6 (0.2) 21.7 (2.1) 94.1 (1.0) 2.9 (0.1) 1.9 (0.1)
1500 45.7 (0.3) 120.4 (0.7) 37.9 (0.3) 30.7 (0.3) 18.6 (0.6) 92.7 (0.6) 2.9 (0.1) 2.0 (0.1)
2000 47.7 (0.9) 121.2 (0.3) 39.4 (0.5) 31.6 (0.3) 18.1 (0.7) 92.9 (0.3) 2.9 (0.0) 2.1 (0.0)
4000 50.9 (0.1) 123.9 (0.4) 41.1 (0.5) 34.1 (0.1) 17.5 (0.4) 94.3 (1.2) 2.8 (0.1) 2.0 (0.1)
MIF = 90 L/min
1000 45.7 (0.2) 121.0 (0.2) 37.8 (0.6) 34.2 (0.6) 17.8 (0.6) 92.5 (0.8) 2.8 (0.1) 2.0 (0.1)
1500 47.7 (0.1) 123.8 (0.8) 38.5 (0.4) 35.1 (0.3) 15.7 (0.4) 93.0 (1.2) 2.8 (0.1) 2.1 (0.1)
2000 53.9 (0.4) 124.6 (0.7) 43.2 (0.6) 38.4 (0.2) 13.3 (0.3) 91.9 (0.7) 2.7 (0.0) 2.0 (0.0)
4000 54.7 (0.4) 126.2 (0.3) 43.4 (0.9) 39.1 (0.9) 12.7 (0.7) 92.6 (1.5) 2.7 (0.0) 2.0 (0.0)
FPD ﬁne particle dose (≤5 μm), TED total emitted dose, FPF ﬁne particle mass as percentage of the TED, EFPD extra ﬁne particle dose
(≤3 μm), RA residual amount (retained in capsule and device), % TRD total recovery dose as percentage of the nominal dose 150 μg
indacaterol, MMAD mass median aerodynamic diameter, GSD geometric standard deviation, MIF maximum inhalation ﬂow, Vin inhaled
volume
Table V. Mean (SD) of the Aerodynamic Characteristics of the Indacaterol 300-μg Dose Emission at Different MIFs and Vins [n = 3]
Vin (mVin (mL) FPD (μg) TED (μg) % FPF EFPD (μg) RA (μg) % TRD MMAD (μm) GSD
MIF = 28.3 L/min
1000 72.9 (1.2) 218.9 (1.7) 33.3 (1.2) 40.5 (0.2) 49.7 (0.9) 89.5 (2.1) 3.3 (0.0) 1.8 (0.1)
1500 83.0 (0.2) 231.0 (1.4) 36.0 (0.3) 45.3 (0.5) 39.2 (1.1) 90.0 (0.9) 3.3 (0.1) 1.9 (0.1)
2000 86.3 (0.4) 232.0 (1.2) 37.2 (0.2) 48.3 (0.3) 38.1 (0.7) 90.1 (1.1) 3.2 (0.0) 1.9 (0.0)
4000 89.8 (1.3) 236.1 (1.0) 38.0 (0.3) 50.0 (0.1) 35.5 (1.3) 90.5 (1.6) 3.0 (0.1) 1.8 (0.0)
MIF = 60 L/min
1000 92.5 (0.4) 240.9 (2.0) 38.4 (0.4) 62.6 (0.5) 36.3 (1.0) 92.4 (2.0) 2.8 (0.0) 2.0 (0.1)
1500 96.0 (0.5) 245.4 (1.3) 39.1 (0.6) 64.4 (0.3) 33.1 (1.2) 92.8 (1.1) 2.8 (0.1) 2.1 (0.1)
2000 99.8 (0.9) 247.8 (1.5) 40.3 (0.7) 66.1 (0.3) 32.9 (0.8) 93.6 (1.3) 2.7 (0.1) 2.0 (0.1)
4000 106.4 (0.6) 249.5 (0.7) 42.7 (0.5) 68.8 (0.8) 31.5 (0.6) 93.6 (1.9) 2.7 (0.0) 2.1 (0.0)
MIF = 90 L/min
1000 95.5 (1.2) 244.1 (1.1) 39.1 (0.8) 74.0 (0.6) 34.6 (0.9) 92.9 (1.2) 2.7 (0.1) 2.0 (0.1)
1500 105.3 (0.8) 246.5 (0.9) 42.7 (0.7) 79.0 (0.3) 30.5 (0.4) 92.3 (1.0) 2.7 (0.0) 1.8 (0.0)
2000 108.5 (0.4) 247.4 (0.7) 43.9 (0.6) 81.1 (0.2) 31.1 (0.8) 92.8 (0.7) 2.6 (0.1) 1.9 (0.1)
4000 112.6 (0.7) 252.1 (1.0) 44.7 (0.9) 82.1 (0.9) 29.1 (0.5) 93.7 (0.8) 2.6 (0.1) 1.9 (0.1)
ﬁne particle dose (≤5 μm), TED total emitted dose, FPF ﬁne particle mass as percentage of the TED, EFPD extra ﬁne particle dose (≤3 μm),
RA residual amount (retained in capsule and device), % TRD total recovery dose as percentage of the nominal dose 300 μg indacaterol,
MMAD mass median aerodynamic diameter, GSD geometric standard deviation, MIF maximum inhalation ﬂow, Vin inhaled volume
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inhalation ﬂow rate, but the mass fraction of particles with
an aerodynamic diameter <3 μm is more pronounced
between 60 and 90 L/min as shown in Fig. 4. The difference
in the drug particle size distribution as a function of the ﬂow
rate and volume is more likely to inﬂuence drug distribution
in the airways.
CONCLUSIONS
The indacaterol dose emission from the capsule-based
Onbrez Breezhaler® for both dose strengths 150 and
300 μg demonstrated inhalation ﬂow-dependent dose
emission. Furthermore, the Vin was important when low
MIF was used. The aerodynamic characteristics of
indacaterol showed that Breezhaler® was effective in
producing respirable particles with an MMAD <5 μm
irrespective of the inhalation ﬂow rate, but the mass
fraction of particles with an aerodynamic diameter <3 μm
is more pronounced between 60 and 90 L/min. The
difference in the drug particle size distribution as a
function of the ﬂow rate and volume is more likely to
inﬂuence drug distribution in the airways.
Overall, the results suggest that a minimum MIF of
60 L/min and inhaled volume are required when using the
indacaterol Breezhaler®. Finally, the results conﬁrm the
recommendation of using two separate inhalations for
each dose, although this is less important at high MIF and
Vin.
ED1 dose emitted after the ﬁrst inhalation, ED2 dose
emitted after the second inhalation, DUSA dose unit
sampling apparatus, ACI Andersen cascade impactor,
DPIs dry powder inhalers, ED emitted dose, FPD ﬁne
particle dose, FPF ﬁne particle fraction, TRD total
recovered dose, HPLC high-performance liquid chroma-
tography, PIFR peak inhalation ﬂow rate, IT inhalation
time, Vin inhaled volume, TED total emitted dose, LOD
limit of detection, LOQ limit of quantiﬁcation, MMAD
mass median aerodynamic diameter, MIF maximum inha-
lation ﬂow, PIL patient information leaﬂets, RA residual
amount, SEM scanning electron microscope, TRA total
residual amount, PSD particle size distribution
Fig. 2. The ﬁne particle dose (FPD) of indacaterol emitted from the Onbrez Breezhaler®
at different MIFs of 28.3, 60 and 90 L/min and Vins of 1, 1.5, 2 and 4 L for both a 150 μg
dose strength and b 300 μg dose strength
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Fig. 3. The extra ﬁne particle dose (EFPD) of indacaterol emitted from the Onbrez Breezhaler® as a function of the
inhalation ﬂow (MIF) and volume (Vin) used for both dose strengths 150 and 300 μg
Fig. 4. The mass median aerodynamic diameter (MMAD) of indacaterol emitted particles at different
inhalation ﬂow (MIF) and inhalation volumes (Vin) for both a 150 μg indacaterol dose strength and b
300 μg indacaterol dose strength
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